Shots:
- The US FDA has approved Camcevi ETM (leuprolide mesylate, 21mg, Q3M LAI) for the treatment of advanced prostate cancer; Application is under the EMA’s review
- Approval was based on P-III trial assessing Camcevi ETM in 144 advanced prostate cancer pts, which showed superior efficacy, with 97.9% pts achieving the 1EP
- Camcevi (Q6M LAI) is being studied in the P-III (Casppian) trial for central precocious puberty as well as a P-III trial for premenopausal breast cancer in China with its partner, & is exclusively licensed to Accord BioPharma for US commercialization
Ref: PRNewsWire | Image: Foresee Pharmaceuticals | Press Release
Related News:- Camurus Receives the MHRA’s Approval for Oczyesa as Maintenance Treatment of Acromegaly
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
